Skip to main content

Advertisement

SpringerLink
Log in

Treatment Targets in the Management of Dyslipidemias: Which Targets in Whom?

  • Lipid Abnormalities and Cardiovascular Prevention (G De Backer, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

The public health approach to prevention of atherosclerotic cardiovascular disease (ASCVD) continues to hold great potential for prevention. This approach includes diets low in saturated fats and cholesterol, maintaining desirable body weight, regular physical activity, and absence of cigarette smoking. But drug therapy is becoming more widely used. Statins have been available for treatment of elevated serum cholesterol for a quarter of a century. They have proven efficacious for reducing risk for atherosclerotic cardiovascular disease (ASCVD). They carry little toxicity, and now that some derivatives are generic, they are inexpensive. Statins have become standard of care for patients with established ASCVD. To achieve further reduction in ASCVD events through cholesterol lowering will require new combinations with older agents and development of new drugs. The future of secondary prevention lies in testing of old and new “add-on” agents. Indications for statin use in primary prevention is less clear-cut. But clinical-trial experience with statins point to enormous potential for reducing ASCVD in the population. At the same time, there are dangers of overuse and turning society into a “drug culture”. To abandon the benefits of healthy lifestyles for excessive drug intervention would be unfortunate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. NCEP Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.

  2. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994;308:367–72.

    Article  CAS  PubMed  Google Scholar 

  3. Grundy SM, Wilhelmsen L, Rose G, et al. Coronary heart disease in high-risk populations: lessons from Finland. Eur Heart J. 1990;11:462–71.

    CAS  PubMed  Google Scholar 

  4. Pietinen P, Lahti-Koski M, Vartiainen E, et al. Nutrition and cardiovascular disease in Finland since the early 1970s: a success story. J Nutr Health Aging. 2001;5:150–4.

    CAS  PubMed  Google Scholar 

  5. • Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999–2008. JAMA. 2010;303:235–41. In 2007–2008, the prevalence of obesity in US adults was 32.2 % among adult men and 35.5 % among adult women. The trend for increasing obesity seems to be diminishing in the past few years. But there was no evidence of decline in obesity in spite of increasing public awareness of the dangers of obesity. The fact that one third of US adults has a BMI over 30 kg/m 2 is consistent with a high prevalence of metabolic syndrome and diabetes in the US population.

    Article  CAS  PubMed  Google Scholar 

  6. Eckel RH. Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation. 1997;96:3248–50.

    Article  CAS  PubMed  Google Scholar 

  7. Kones R. Is prevention a fantasy, or the future of medicine? a panoramic view of recent data, status, and direction in cardiovascular prevention. Ther Adv Cardiovasc Dis. 2011;5:61–81.

    Article  PubMed  Google Scholar 

  8. Centers for Disease Control and Prevention. Vital signs: current cigarette smoking among adults aged ≥18 years–United States, 2005–2010. MMWR Morb Mortal Wkly Rep. 2011;60:1207–12.

    Google Scholar 

  9. WHO. Report on the global tobacco epidemic: the MPOWER package. Geneva; 2008.

  10. Bullen C. Impact of tobacco smoking and smoking cessation on cardiovascular risk and disease. Expert Rev Cardiovasc Ther. 2008;6:883–95.

    Article  CAS  PubMed  Google Scholar 

  11. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 1992;33:1569–82.

    CAS  PubMed  Google Scholar 

  12. Golomb BA, Evans MA, Dimsdale JE, et al. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med. 2012; [Epub ahead of print].

  13. • Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomized trials. Lancet. 2010;376:1670–81. This study was a meta-analysis of statin trials comparing more vs less intensive statin therapy. For each 1.0 mmol/L reduction in LDL there was just over a fifth reduction in major vascular events. There was no evidence of a threshold within the range studied. However, the data do not include studies in which very low LDL concentrations were obtained, so this study does not prove “the lower, the better” at very low LDL levels. This study expands the CTT set of meta-analysis on the efficacy of LDL-lowering therapy in a large number of randomized trials. It provides convincing evidence that LDL lowering is both efficacious and safe. It is an important contribution to the field.

    Article  CAS  PubMed  Google Scholar 

  14. • Gutierrez J, Ramirez G, Rundek T, et al. Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis statin therapy to prevent recurrent CV events. Arch Intern Med. 2012;172:909–19. This analysis indicates that statin therapy reduces all cardiovascular events in both men and women. However, for women, it was not possible to demonstrate a reduction in stroke or total mortality, as occurs in men. A question to be asked about this conclusion is whether the accumulated trial data in women is robust enough to draw this conclusion.

    Article  CAS  PubMed  Google Scholar 

  15. Abramson J, Wright JM. Are lipid-lowering guidelines evidence-based? Lancet. 2007;369:168–9.

    Article  CAS  PubMed  Google Scholar 

  16. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.

    Article  CAS  PubMed  Google Scholar 

  17. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351–64.

  18. • Vega GL, Dunn FL, Grundy SM. Effect of colesevelam hydrochloride on glycemia and insulin sensitivity in men with the metabolic syndrome. Am J Cardiol. 2011;108:1129–35. This study shows that bile acid sequestrants are effective as add-on therapy to statins even at LDL levels less than 100 mg/dL.

    Article  CAS  PubMed  Google Scholar 

  19. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245–55.

    Article  CAS  PubMed  Google Scholar 

  20. Canner PL, Furberg CD, Terrin ML, et al. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol. 2005;95:254–7.

    Article  CAS  PubMed  Google Scholar 

  21. Brown BG, Zhao XQ. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Am J Cardiol. 2008;101:58B–62B.

    Article  CAS  PubMed  Google Scholar 

  22. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin. 2006;22:2243–50.

    Article  CAS  PubMed  Google Scholar 

  23. • AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–67. The AIM-HIGH trial randomly assigned 3414 patients to extended-release niacin, 1500 to 2000 mg per day, or matching placebo. In addition patients received simvastatin, 40 to 80 mg per day, plus ezetimibe, 10 mg per day, to maintain an LDL cholesterol level of 40 to 80 mg per deciliter (1.03 to 2.07 mmol per liter). The trial was terminated 3 years due to an apparent lack of efficacy. Niacin moderated raised HDL and reduced triglyceride and LDL. After 3 years, there apparently was no clinical benefit from adding niacin to statin therapy. This trial was relatively small and was of relatively short duration. Whether a larger and longer trial would have shown a benefit must be weighed on a longer trial now being carried out.

    Article  PubMed  Google Scholar 

  24. Grundy SM, Vega GL. Fibric acids: effects on lipids and lipoprotein metabolism. Am J Med. 1987;83:9–20.

    Article  CAS  PubMed  Google Scholar 

  25. • Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375:1875–84. This meta-analysis included 18 trials involving 45,058 participants and 2870 major cardiovascular events, 4552 coronary events, and 3880 deaths. In this analysis, fibrate therapy produced a significant 10 % relative risk reduction for major cardiovascular events, and a 13 % relative risk reduction for coronary events, but had no benefit on stroke or all-cause mortality. Subgroup analysis showed a greater effect in subjects with a higher mean baseline triglyceride concentration.

    Article  CAS  PubMed  Google Scholar 

  26. • Lee M, Saver JL, Towfighi A, et al. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis. 2011;217:492–8. This meta-analysis was carried out in fibrate trials and in subjects identified as having atherogenic dyslipidemia (serum high density lipoprotein cholesterol [HDL-C] <40 mg/dl or triglycerides >200 mg/dl). Six trials having 7389 subjects with high triglycerides met selection criteria. In this subgroup, relative risk reduction for major coronary events was 25 % (P < 0.001). In 5068 subjects with both high triglycerides and low HDL-C, fibrates reduced risk by 29 % (P < 0.001). This study strongly supports a benefit of fibrate therapy in hypertriglyceridemic subjects.

  27. Bays HE, Moore PB, Drehobl MA, Ezetimibe Study Group, et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther. 2001;23:1601–30. Erratum in: Clin Ther. 2001;23:1601.

    Article  CAS  Google Scholar 

  28. Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343–56.

    Article  PubMed  Google Scholar 

  29. Cannon CP, Giugliano RP, Blazing MA, IMPROVE-IT Investigators, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin vs simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008;156:826–32.

    Article  CAS  PubMed  Google Scholar 

  30. Bays HE, Shah A, Macdonell G, et al. Effects of coadministered ezetimibe plus fenofibrate in mixed dyslipidemic patients with metabolic syndrome. Metab Syndr Relat Disord. 2011;9:135–42.

    Article  CAS  PubMed  Google Scholar 

  31. • Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366:1108–18. In this dose ranging study, a monoclonal antibody to PCSK9 significantly lowered LDL cholesterol levels in healthy volunteers and in subjects with familial or nonfamilial hypercholesterolemia. The antibody was well tolerated. This study shows the potential of PCSK9 inhibitors as either an alternative to statins or as an add-on drug. However, this approach must be tested for clinical efficacy and safety.

    Article  CAS  PubMed  Google Scholar 

  32. • Cannon CP, Shah S, Dansky HM, et al. Determining the efficacy and tolerability investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406–15. Inhibitors of cholesterol-ester transfer protein (CETP) raise HDL cholesterol and also raised LDL cholesterol. Anacetrapib is in phase 3 trials to determine its efficacy and safety.

  33. Akdim F, Visser ME, Tribble DL, et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol. 2010;105:1413–9.

    Article  CAS  PubMed  Google Scholar 

  34. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007;356:148–56.

    Article  CAS  PubMed  Google Scholar 

  35. Bryzgalova G, Effendic S, Khan A, et al. Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB-141. J Steroid Biochem Mol Biol. 2008;111:262–7.

    Article  CAS  PubMed  Google Scholar 

  36. Suckling K. Phospholipase A2s: developing drug targets for atherosclerosis. Atherosclerosis. 2010;212:357–66.

    Article  CAS  PubMed  Google Scholar 

  37. Cohen JC, Boerwinkle E, Mosley Jr TH, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264–72.

    Article  CAS  PubMed  Google Scholar 

  38. Smith Jr SC, Benjamin EJ, Bonow RO, World Heart Federation and the Preventive Cardiovascular Nurses Association, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124:2458–73.

    Article  PubMed  Google Scholar 

  39. Catapano AL, Reiner Z, De Backer G, European Society of Cardiology (ESC); European Atherosclerosis Society (EAS), et al. ESC/EAS guidelines for the management of dyslipidaemias. The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217:3–46.

    Article  CAS  PubMed  Google Scholar 

  40. Amarenco P, Bogousslavsky J, Callahan III A, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549–59.

    Article  CAS  PubMed  Google Scholar 

  41. Amarenco P, Labreuche J, Lavallée P, et al. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke. 2004;35:2902–9.

    Article  CAS  PubMed  Google Scholar 

  42. D’Agostino Sr RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743–53.

    Article  PubMed  Google Scholar 

  43. Conroy R, Pyorala K, Fitzgerald AP, et al. Estimation of 10 year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003.

    Article  CAS  PubMed  Google Scholar 

  44. • Cholesterol Treatment Trialists’ (CTT) Collaborators. The effects of lowering LDL cholesterol with statin meta-analysis of individual data from 27 randomized trials. Lancet. [published online May 16, 2012]. The authors report in this meta-analysis that major vascular events in persons with 10 year risk lower than 10 %, each 1 mmol/L reduction in LDL cholesterol produced an absolute reduction in major vascular events of about 11 per 1000 over 5 years. They postulate that this benefit greatly exceeds hazards of statin therapy. Under present guidelines, such individuals with this risk range are regarded as suitable for LDL-lowering statin therapy. But considering the benefit obtained in this analysis, current guidelines should be reconsidered.

  45. American Diabetes Association. Standards of medical care in diabetes–2012. Diabetes Care. 2012;35 Suppl 1:S11–63.

    Google Scholar 

  46. • Scott R, O’Brien R, Fulcher G, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9795 individuals with type 2 diabetes and various components of the metabolic syndrome. Diabetes Care. 2009;32:493–8. Subgroup analysis of the FIELD trial suggests that fenofibrate therapy is efficacious in the subgroup with elevated triglycerides.

    Article  CAS  PubMed  Google Scholar 

  47. • The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–74. Subgroup analysis of the ACCORD trial suggests that fenofibrate therapy is efficacious in the subgroup with elevated triglycerides.

    Article  Google Scholar 

  48. • Elam M, Lovato LC, Ginsberg H. Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective. Curr Opin Lipidol. 2011;22:55–61. Subgroup analysis of the ACCORD trial suggests that fenofibrate therapy is efficacious in the subgroup with elevated triglycerides.

    Article  CAS  PubMed  Google Scholar 

  49. Fink HA, Ishani A, Taylor BC, et al. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2012;156:570–81.

    PubMed  Google Scholar 

  50. Wanner C, Krane V, März W, German Diabetes and Dialysis Study Investigators, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–48. Erratum in: N Engl J Med. 2005;353:1640.

    Article  CAS  PubMed  Google Scholar 

  51. Fellström BC, Jardine AG, Schmieder RE, for the AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395–407.

    Article  PubMed  Google Scholar 

  52. Holdaas H, Fellström B, Jardine AG, on behalf of the Assessment of LEscol in Renal Transplantation (ALERT). Study investigates effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicenter, randomized, placebo-controlled trial. Lancet. 2003;361:2024–31.

    Article  CAS  PubMed  Google Scholar 

  53. • Baigent C, Landray MJ, Reith C, SHARP Investigators, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial. Lancet. 2011;377:2181–92. This large clinical trial demonstrates that LDL lowering is efficacious in patients with chronic kidney disease. The study largely negates smaller trials that questioned the benefit. The results reassure that statin therapy is indicated in patients with chronic kidney disease who are deemed to be at higher risk for atherosclerotic cardiovascular disease.

    Article  CAS  PubMed  Google Scholar 

  54. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5.

    Article  CAS  PubMed  Google Scholar 

  55. Grundy SM, Cleeman JI, Daniels SR, American Heart Association; National Heart, Lung, and Blood Institute, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–52. Erratum in: Circulation. 2005;112:e298. Circulation. 2005;112:e297. PubMed PMID: 16157765.

    Article  PubMed  Google Scholar 

  56. Deedwania P, Barter P, Carmena R, Treating to New Targets (TNT) Investigators, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006;368:919–23.

    Article  CAS  PubMed  Google Scholar 

  57. Grundy SM. Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol. 2012;59:635–43.

    Article  CAS  PubMed  Google Scholar 

  58. The DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161:397–405.

    Article  Google Scholar 

  59. Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol. 2010;55:1310–7.

    Article  PubMed  Google Scholar 

  60. Assmann G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J. 1998;19(Suppl M):M8–M14.

    PubMed  Google Scholar 

  61. Ewald N, Hardt PD, Kloer HU. Severe hypertriglyceridemia and pancreatitis: presentation and management. Curr Opin Lipidol. 2009;20:497–504.

    Article  CAS  PubMed  Google Scholar 

  62. Isaacsohn J, Hunninghake D, Schrott H, et al. Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia. Clin Cardiol. 2003;26:18–24.

    Article  PubMed  Google Scholar 

  63. Shepherd J, Blauw GJ, Murphy MB, PROspective Study of Pravastatin in the Elderly at Risk, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet. 2002;360:1623–30.

    Article  CAS  PubMed  Google Scholar 

  64. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomized controlled trials. Br Med J. 2009;338:b2376.

    Article  CAS  Google Scholar 

  65. Downs JR, Clearfield M, Whitney E, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA. 1998;279:1615–22.

    Article  CAS  PubMed  Google Scholar 

  66. Kathiresan S, Myocardial Infarction Genetics Consortium. A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction. N Engl J Med. 2008;358:2299–300.

    Article  CAS  PubMed  Google Scholar 

  67. Brown MS, Goldstein JL. Biomedicine. Lowering LDL–not only how low, but how long? Science. 2006;311:1721–3.

    Article  CAS  PubMed  Google Scholar 

  68. • Domanski M, Lloyd-Jones D, Fuster V, et al. Can we dramatically reduce the incidence of coronary heart disease? Nat Rev Cardiol. 2011;8:721–5. This review makes the case for a large clinical trial to address whether long-term statin therapy starting in young adult men or recent post-menopausal women will largely abolish coronary heart disease in the general population.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

Conflicts of interest: S.M. Grundy: has been a consultant for Merck and Pfizer; and has received honoraria from Boston Partners.

Author information

Authors and Affiliations

  1. Center for Human Nutrition, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Suite Y3.206, Dallas, TX, 75390-9052, USA

    Scott M. Grundy

Authors
  1. Scott M. Grundy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Scott M. Grundy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grundy, S.M. Treatment Targets in the Management of Dyslipidemias: Which Targets in Whom?. Curr Cardiol Rep 14, 692–700 (2012). https://doi.org/10.1007/s11886-012-0305-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-012-0305-7

Keywords

Search

Navigation